Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 494

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Open access
Moore, Kathleen N., Angelergues, Antoine, Konecny, Gottfried E., García, Yolanda, Banerjee, Susana, Lorusso, Domenica, Lee, Jung-Yun, Moroney, John W., Colombo, Nicoletta, Roszak, Andrzej, Tromp, Jacqueline, Myers, Tashanna, Lee, Jeong-Won, Beiner, Mario, Cosgrove, Casey M., Cibula, David, Martin, Lainie P., Sabatier, Renaud, Buscema, Joseph, Estévez-García, Purificación, Coffman, Lan, Nicum, Shibani, Duska, Linda R., Pignata, Sandro, Gálvez, Fernando, Wang, Yuemei, Method, Michael, Berkenblit, Anna, Bello Roufai, Diana, Van Gorp, Toon·2023·New England Journal of Medicine

Abstract

BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. METHODS: We conducted a phase 3, global, confirmatory, open-label, randomized, controlled trial to compare the efficacy and safety of MIRV with the investigator's choice of chemotherapy in the treatment of platinum-resistant, high-grade serous ovarian cancer. Participants who had previously received one to three lines of therapy and had high FRα tumor expression (≥75% of cells with ≥2+ staining intensity) were randomly assigned in a 1:1 ratio to receive MIRV (6 mg per kilogram of adjusted ideal body weight every 3 weeks) or chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The primary end point was investigator-assessed progression-free survival; key secondary analytic end points included objective response, overall survival, and participant-reported outcomes. RESULTS: A total of 453 participants underwent randomization; 227 were assigned to the MIRV group and 226 to the chemotherapy group. The median progression-free survival was 5.62 months (95% confidence interval [CI], 4.34 to 5.95) with MIRV and 3.98 months (95% CI, 2.86 to 4.47) with chemotherapy (P<0.001). An objective response occurred in 42.3% of the participants in the MIRV group and in 15.9% of those in the chemotherapy group (odds ratio, 3.81; 95% CI, 2.44 to 5.94; P<0.001). Overall survival was significantly longer with MIRV than with chemotherapy (median, 16.46 months vs. 12.75 months; hazard ratio for death, 0.67; 95% CI, 0.50 to 0.89; P = 0.005). During the treatment period, fewer adverse events of grade 3 or higher occurred with MIRV than with chemotherapy (41.7% vs. 54.1%), as did serious adverse events of any grade (23.9% vs. 32.9%) and events leading to discontinuation (9.2% vs. 15.9%). CONCLUSIONS: Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response. (Funded by ImmunoGen; MIRASOL ClinicalTrials.gov number, NCT04209855.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2309169

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 494

Metadata

Authors
Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J.-Y., Moroney, J. W., Colombo, N., Roszak, A., Tromp, J., Myers, T., Lee, J.-W., Beiner, M., Cosgrove, C. M., Cibula, D., Martin, L. P., Sabatier, R., Buscema, J., Estévez-García, P., Coffman, L., Nicum, S., Duska, L. R., Pignata, S., Gálvez, F., Wang, Y., Method, M., Berkenblit, A., Bello Roufai, D., & Van Gorp, T.
Venue
New England Journal of Medicine
Published
2023-12-07
Volume
389
Issue
23
Pages
2162-2174
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4389376362
Cited by
494
References
20
FWCI
94.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2309169
The paper
Moore, K. N., Angelergues, A., Konecny, G. E., García, Y., Banerjee, S., Lorusso, D., Lee, J.-Y., Moroney, J. W., Colombo, N., Roszak, A., Tromp, J., Myers, T., Lee, J.-W., Beiner, M., Cosgrove, C. M., Cibula, D., Martin, L. P., Sabatier, R., Buscema, J., . . . Van Gorp, T. (2023). Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2309169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.